Venous thromboembolism (VTE)

Award for new blood clot prevention technology

A partnership between the Royal Stoke University Hospital, part of the University Hospitals of North Midlands NHS Trust, and a UK industry-leading medical devices company have been rewarded for its use of an innovative bioelectronic technology to prevent life-threatening blood clots in acute stroke patients – winning in the category: Best use of technology (acute care), at the Building Better Healthcare Awards.

The collaboration, a partnership between the Royal Stoke and UK-based Sky Medical Technology (Sky), investigated though a prospective study of two care pathways, the  use of the company's geko device in preventing venous thromboembolism (VTE), blood clots, in high-risk patients at the hospital's leading Stroke Unit.

VTE is a major risk to hospitalised patients, with an estimated 40,000 deaths in England annually, 62 per cent of which are preventable given proper management – with acute stroke patients being a high at-risk population due to reduced mobility. The geko device (approved by NICE), is the size of a wristwatch and worn at the knee. The daily disposable device gently stimulates the common peroneal nerve activating the calf and foot muscle pumps, resulting in increased blood flow in the deep veins of the calf.

Photo

The comparative study assessed 1,000 acute stroke patients for VTE incidence at 90 days post discharge and reported 0% VTE in patients wearing the geko device alone, along with good patient tolerance, compared to VTE in patients prescribed intermittent pneumatic compression devices (IPC) at 2.4% or pharmacological prophylaxis at 0.8%.

The investigators, led by Mr. Indira Natarajan, consultant stroke physician and clinical director for neurosciences and Professor Christine Roffe, determined that 30% of patients are contraindicated or became intolerant to IPC (discomfort or dislike to IPC). It is to this unmet need cohort that the geko device was fitted, reporting a zero VTE incidence and good patient tolerance. Commenting on behalf of the Royal Stoke University Hospital, Mr Indira Natarajan said: "We are thrilled to win this award, and our thanks go to the Building Better Healthcare team for recognising our use of innovative technology to address this important unmet need. I would also like to thank Sky. The geko device marks a significant change to our nursing practice when other VTE prevention strategies are contraindicated or impractical, and provides an option where previously patients would have had no other intervention available to them."

Also commenting, Bernard Ross, CEO Sky Medical Technology said: "The 1,000 patient data set has not only changed clinical practice nationally – over 27 NHS Hospitals are actively working to embed the geko device within their acute stroke care pathways – the data also helped to secure FDA 510(k) clearance, making the geko the first device of its kind to be cleared for VTE prevention across all patients, including non-surgical patients in the USA. This tremendous success demonstrates the huge potential of industry and NHS partnering, and it is to the Royal Stoke team that we owe our sincere thanks. Without their commitment, passion and willingness to embrace innovation, none of this would be possible."


Source: University Hospitals of North Midlands NHS Trust

13.11.2019

Read all latest stories

Related articles

Photo

Anticoagulants vs coronavirus

Preventive blood thinning could reduce risk of Covid-19 death

Patients given preventive blood thinning drugs (prophylactic anticoagulants) within 24 hours of admission to hospital with Covid-19 are less likely to die compared with those who do not receive them,…

Photo

Thromboembolic misunderstandings

Covid-19, not vaccination, presents biggest blood clot risks

Researchers from the University of Oxford have announced the results of a study into thrombocytopenia (a condition with low platelet counts) and thromboembolic events (blood clots) following…

Photo

Covid-19 prevention side effects

Rare blood clots after Oxford-AstraZeneca vaccine: study sheds more light

A large study from Denmark and Norway published by The BMJ sheds more light on the risk of rare blood clots in adults receiving their first dose of the Oxford-AstraZeneca Covid-19 vaccine. The…

Related products

Siemens Healthineers – Sysmex CA-600 Systems

Hemostaseology

Siemens Healthineers – Sysmex CA-600 Systems

Siemens Healthineers
Siemens Healthineers – Sysmex CS-2500 System

Hemostaseology

Siemens Healthineers – Sysmex CS-2500 System

Siemens Healthineers
Teco – Coatron X

Hemostaseology

Teco – Coatron X

TECO Medical Instruments
Alsachim - Dosimmune immunosupressant Alsachim – kit (CE-IVD or RUO)

Clinical Chemistry

Alsachim - Dosimmune immunosupressant Alsachim – kit (CE-IVD or RUO)

Alsachim, a Shimadzu Group Company
Alsachim – Dosinaco anticoagulant reagent kit (RUO)

Clinical Chemistry

Alsachim – Dosinaco anticoagulant reagent kit (RUO)

Alsachim, a Shimadzu Group Company
ASP Lab Automation – Bench-top Decapper DeCap Pro

Sample Processing

ASP Lab Automation – Bench-top Decapper DeCap Pro

ASP Lab Automation AG
Subscribe to Newsletter